文献速递骨软组织肉瘤与黑色素瘤

NY-ESO-1 c259T细胞在滑膜肉瘤中持久存续并关联抗肿瘤活性

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.
PubMed 文献 · Cancer Discov · 2018-06-11

该研究评估了表达NY-ESO-1c259(一种亲和力增强的TCR)的自体T细胞在转移性滑膜肉瘤患者中的安全性和活性。确认的抗肿瘤反应发生于50%(6/12)的患者,所有患者输注后均可检测到循环NY-ESO-1c259T细胞,所有应答者持续至少6个月。持久存续的T细胞池主要为中央记忆和干细胞记忆亚群,保持多功能且无耗竭证据。

要点

  • 转移性滑膜肉瘤中确认抗肿瘤反应率为50%(6/12)。
  • 所有应答者循环NY-ESO-1c259T细胞持续至少6个月。
  • 持久存续池以中央记忆和干细胞记忆亚群为主,无T细胞耗竭证据。

核心结论

  • NY-ESO-1c259T细胞在转移性滑膜肉瘤中显示临床有意义的抗肿瘤活性,与T细胞持久存续相关。

研究设计与样本

  • 研究评估自体NY-ESO-1c259T细胞在转移性滑膜肉瘤患者中的安全性和活性,共12例可评估患者。

主要发现

  • 确认的抗肿瘤反应发生于50%(6/12)的患者,表现为数月内肿瘤缩小。
  • 所有患者输注后均可检测到循环NY-ESO-1c259T细胞,所有应答者持续至少6个月。
  • 输注的NY-ESO-1c259T细胞体外扩增后多数为效应记忆表型,但持久存续池主要为中央记忆和干细胞记忆亚群。
  • 持久存续的T细胞保持多功能且无T细胞耗竭证据,尽管存在持续肿瘤负荷。
  • CD8+ NY-ESO-1c259T细胞的内源性TCR下一代测序显示克隆多样性随时间未收缩。

临床怎么用

  • 对于标准治疗不可治愈的转移性滑膜肉瘤,靶向NY-ESO-1的工程化T细胞可能提供持续抗肿瘤效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2-restricted NY-ESO-1/LAGE1a-derived peptide, in patients with metastatic synovial sarcoma (NY-ESO-1c259T cells). Confirmed antitumor responses occurred in 50% of patients (6/12) and were characterized by tumor shrinkage over several months. Circulating NY-ESO-1c259T cells were present postinfusion in all patients and persisted for at least 6 months in all responders. Most of the infused NY-ESO-1c259T cells exhibited an effector memory phenotype following ex vivo expansion, but the persisting pools comprised largely central memory and stem-cell memory subsets, which remained polyfunctional and showed no evidence of T-cell exhaustion despite persistent tumor burdens. Next-generation sequencing of endogenous TCRs in CD8+ NY-ESO-1c259T cells revealed clonal diversity without contraction over time. These data suggest that regenerative pools of NY-ESO-1c259T cells produced a continuing supply of effector cells to mediate sustained, clinically meaningful antitumor effects.Significance: Metastatic synovial sarcoma is incurable with standard therapy. We employed engineered T cells targeting NY-ESO-1, and the data suggest that robust, self-regenerating pools of CD8+ NY-ESO-1c259T cells produce a continuing supply of effector cells over several months that mediate clinically meaningful antitumor effects despite prolonged exposure to antigen. Cancer Discov; 8(8); 944-57. ©2018 AACR.See related commentary by Keung and Tawbi, p. 914This article is highlighted in the In This Issue feature, p. 899.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. D'Angelo SP, Melchiori L, Merchant MS, et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov. 2018. PMID: 29891538. doi:10.1158/2159-8290.CD-17-1417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。